Open Access Open Access  Restricted Access Access granted  Restricted Access Subscription or Fee Access

No 4 (2012)

Articles

CONTRACEPTIVE METHODS IN WOMEN WITH EPILEPSY

Adamyan L., Zhidkova I.A., Berseneva V.V., Kaznacheeva T.V., Adamyan L.V., Zhidkova I.A., Berseneva V.V., Kaznacheyeva T.V.

Abstract

Epilepsy is an important clinical interdisciplinary problem. It is known that about half of epileptic patients are women, and over 40% of them are women of reproductive age. The problem of reproductive health of women with epilepsy involves individual choice of contraceptive method that is acceptable for a given patient, depending on receiving antiepileptic therapy. Currently, the questions of choice of contraceptive methods for epileptic women using various antiepileptic drugs are poorly understood, and planning for pregnancy requires joint counseling and management by neurologist and obstetrician-gynecologist.
Pharmateca. 2012;(4):14-19
pages 14-19 views

CONTROVERSIAL ISSUES OF ARTERIAL HYPERTENSION DURING PREGNANCY

Tkacheva O.N., Runikhina N.K., Chukhareva N.A., Sharashkina N.V., Tkacheva O.N., Runikhina N.K., Chukhareva N.A., Sharashkina N.V.

Abstract

There are many inconsistent positions in the approaches to the management of pregnant women with arterial hypertension (AH). Russian multicenter epidemiological studies Medical and diagnostic tactics for pregnant women with arterial hypertension in Russia DIALOGUE and DIALOGUE II have shown that currently there is no single approach to the formulation of the diagnosis and treatment strategy in clinical practice. In pregnancy, choice of drugs is very limited; many drugs with proven efficacy in AH have contraindications for the use in pregnancy and lactation. Based on analysis of recent clinical recommendations of Society of Cardiology of Russian Federation and foreign societies dealing with the problem of AH in pregnancy, the article discusses the controversial issues of management of pregnant women with AH.
Pharmateca. 2012;(4):20-26
pages 20-26 views

URINARY INCONTINENCE IN MEN

Markosyan T.G., Korchazhkina N.B., Nikitin S.S., Markosyan T.G., Korchazhkina N.B., Nikitin S.S.

Abstract

The article presents a comprehensive overview of the current literature on urinary incontinence in men. Data for various forms of urinary incontinence, including those arising after the surgery for prostate diseases, as well as information concerning diagnosis and treatment are evaluated and presented. Features of the nervous regulation of urination and the role of denervation processes in pelvic organs in the formation of urinary incontinence are described in detail. The article also presents own authors clinical material (n = 14) for features of diagnostics of neurogenic component of incontinence. Normative reference for the electromyographic activity of pelvic floor muscles and the corticospinal tract conductivity is developed in the group of healthy volunteers (n = 14). Significant denervation-reinnervation changes in pelvic floor, characterized by elongation of central motor conduction time, presence of positive sharp waves and fibrillation potentials, and polyphasy of action potentials of muscle units, are revealed in all patients. The identified changes are taken into account in the choice of treatment strategy; drugs that enhance trophic nutrition and conductivity of nerve tissue, as well as extracorporeal magnetic stimulation of the muscles of the perineum were used.
Pharmateca. 2012;(4):27-31
pages 27-31 views

THE ROLE OF MAGNESIUM-CONTAINING DRUGS IN TREATMENT OF ARRHYTHMIAS

Mubarakshina O.A., Kurbatova E.I., Mubarakshina O.A., Kurbatova Y.I.

Abstract

The review discusses current issues of etiology of cardiac arrhythmias, and the place of magnesium-containing preparations in the classification of antiarrhythmic drugs. Modern data on the problem of magnesium deficiency and its effects on heart rate and functions of the cardiovascular system, the possibility of correction of different types of arrhythmias using magnesium-containing drugs are presented. The role of orotic acid in the body and its effects on the cardiovascular system are discussed; principles of action of drug Magnerot and main indications for its use, including in the pediatric and obstetric practice, are presented.
Pharmateca. 2012;(4):32-36
pages 32-36 views

ANEMIA IN WOMEN: WHAT INTERNISTS SHOULD KNOW?

Napalkov D.A., Panferov A.S., Napalkov D.A., Panferov A.S.

Abstract

The prevalence of anemia among pregnant and nonpregnant women is significantly higher than among men. In routine practice, therefore, physicians often have to deal with the diagnosis and treatment of anemia in women. This literature review considers the most frequent clinical situations in daily practice of clinician detecting anemia in women: anemia in pre-and postmenopausal women, often associated with overweight and obesity, anemia of chronic disease, anemia due to intense metrorrhagia and anemia in pregnant women
Pharmateca. 2012;(4):37-41
pages 37-41 views

NEW ASPECTS OF CLINICAL EFFECTIVENESS OF TYPE 5 PHOSPHOTIDYL ESTERASE INHIBITORS IN THE TREATMENT OF PATIENTS WITH ERECTILE DYSFUNCTION

Gamidov S.I., Ovchinnikov R.I., Popova A.Y., Kramareva K.I., Hamidov S.I., Ovchinnikov R.I., Popova A.Y., Kramareva K.I.

Abstract

Some new approaches to evaluating the effectiveness of vardenafil (Levitra) and other phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction are presented. In particular, along with traditional methods of assessing the clinical effects of Levitra, a number of studies have used a special technique that allowed to evaluate the effect of this drug on the satisfaction of the sexual life of female partners of patients. It was shown that Levitra increases the degree of their satisfaction with sexual intercourse. The reason for this is that treatment with Levitra is accompanied by significant increase in the duration of erection, including in patients with metabolic syndrome. The beneficial effects of vardenafil (Levitra) on the duration of erection and satisfaction of sex life partners of patients are additional confirmations of the high clinical efficacy of this drug.
Pharmateca. 2012;(4):42-46
pages 42-46 views

EFFICACY OF LONGIDAZA IN COMBINED THERAPY OF PERITONEAL COMMISSURES OF PELVIC ORGANS IN ENDOMETRIOSIS

Smirnova L.E., Umakhanova M.M., Torchinov A.M., Smirnova L.Y., Umakhanova M.M., Torchinov A.M.

Abstract

The article considers the modern view on endometriosis (EM), pathogenesis, clinical presentation and complications of the disease, in particular the adhesive process in the pelvis with involvement of the fallopian tubes caused by hyperplasia of connective tissue. The data for evaluation of clinical efficacy of drug Longidaza compared with the drug Lydase in 50 women aged 21-40 years with various forms of EM, complicated by adhesive process in pelvic organs and tubo-peritoneal infertility are presented. Longidaza was superior to Lydase in terms of efficacy. These results suggest that choice of Longidaza for the prevention and treatment of adhesive process in pelvic organs in patients with EM is justified.
Pharmateca. 2012;(4):48-51
pages 48-51 views

[6S]-5-METHYLTETRAHYDROFOLATE INCREASES PLASMA FOLATE MORE EFFECTIVELY THAN FOLIC ACID IN WOMEN WITH THE HOMOZYGOUS OR WILD-TYPE 677C,T POLYMORPHISM OF METHYLENETETRAHYDROFOLATE REDUCTASE *

Prints-Langekhol' R., Bremsvig S., Tobol'ski O., Smul'ders U.M., Smit D.E., Finglas P.M., P'etrtsik L., Prinz-Langenohl R., Brämswig S., Tobolski O., Smulders Y., Smith D., Finglas P., Pietrzik L.

Abstract

Folic acid (FA) at a dosage of 400 mg/day is recommended for all women of reproductive age as a measure for primary prevention of neural tube defects in future offspring. Randomized double-blind, crossover clinical study, including apparently healthy women with 5,10-methylenetetrahydrofolate reductase (677S → T polymorphism) gen mutation in the TT or CC genotype, has shown that the appointment of supplement [6S] -5 -methyltetrahydrofolate ([6S]-5-MTHF) in physiological doses for a short period increases plasma folate more effectively than FA, regardless of the genotype of the mutation. There is no information about serious side effects of a [6S]-5-MTHF, hence, preparations based on this natural biologically active form of folate can be considered as an alternative to FA.
Pharmateca. 2012;(4):52-59
pages 52-59 views

SIDE EFFECTS OF ANTIEPILEPTIC DRUGS ON REPRODUCTIVE HEALTH IN WOMEN WITH EPILEPSY

Odintsova G.V., Saykova L.A., Odintsova G.V., Saykova L.A.

Abstract

The place of side effects of antiepileptic drugs (AEDs) on reproductive health in the classifications of drug side effects is determined, their frequency was investigated in a cohort of 155 women of reproductive age with epilepsy observed in a specialized Department of Epilepsy in the Institute of Human Brain. Patients were divided into 3 groups: Group 1 received monotherapy with AEDs, Group 2 - polytherapy with AEDs, Group 3 did not receive AEDs. Main characteristics of epilepsy were not significant different between groups, except predominance of very frequent seizures in the polytherapy group. It is established that reproductive health disorders are common side effects of AEDs in women with epilepsy. In total cohort, the frequency of side effects was 40%. Reproductive endocrine disorders were statistically more frequent in the AED groups compared with the control group. AED polytherapy of epilepsy in women increases the incidence of reproductive disorders (58.5% compared with 10% in the control group).
Pharmateca. 2012;(4):60-64
pages 60-64 views

NEW TREATMENT OF CHRONIC PROSTATITIS: INTERFERON GAMMA

Pushkar' D.Y., Kasyan G.R., Pushkar D.Y., Kasyan G.R.

Abstract

The article presents the results from prospective open controlled study on efficacy and safety of the drug Ingaron (interferon gamma - IFN-γ) in 30 patients with chronic prostatitis (CP). Patients of the first group (n = 15) received standard therapy for CP (fluoroquinolone antibiotic and α-blocker) in combination with IFN-γ at a dose of 500 000 IU, patients of the control group (n = 15) - only standard therapy without the use of IFN. According to the results of study, of anti-relapse action of Ingaron persists for 6 months in 66.7% of patients of experimental group versus 20% of patients of control group after completion of treatment. Protracted treatment with Ingaron at the recommended dosage is safe and well tolerable, and can be recommended for the complex treatment of CP patients.
Pharmateca. 2012;(4):65-67
pages 65-67 views

CITRATE THERAPY FOR UROLITHIASIS

Shpot' E.V., Sultanova E.A., Shpot Y.V., Sultanova Y.A.

Abstract

The article discusses the problem of urolithiasis, the causes of nephrolithiasis and treatment of urolithiasis. Particular attention is paid to litholitic citrate therapy. The results of own authors research are presented. Citrate therapy with drug Blemaren was administered in 35 patients for 4 months; there were patients with large urate renal stones, patients who had undergone percutaneous nephrolithotomy, and patients with ureteral stones against the background of the upper urinary tract drainage by catheter-stent. Complete litholysis was observed in 19 (54.3%) patients, and reduction of stone sizes - in 12 patients (34.2%) that provided the prospects for further litholysis against the background of therapy with Blemaren.
Pharmateca. 2012;(4):68-71
pages 68-71 views

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies